Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV-Reference-Cited by-同舟云学术

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV

Published:2022-03-16 Issue:9 Volume:23 Page:936-946
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Orkin Chloe¹,Cahn Pedro²³,Castagna Antonella⁴,Emu Brinda⁵,Harrigan P Richard⁶,Kuritzkes Daniel R.⁷,Nelson Mark⁸,Schapiro Jonathan⁹

Affiliation:

1. Queen Mary University London London UK

2. Fundacion Huesped Buenos Aires Argentina

3. Buenos Aires University Medical School Buenos Aires Argentina

4. Vita‐Salute San Raffaele University San Raffaele Scientific Institute Milan Italy

5. Yale School of Medicine New Haven Connecticut USA

6. University of British Columbia Vancouver BC Canada

7. Brigham and Women’s Hospital Harvard Medical School Boston Massachusetts USA

8. Chelsea and Westminster Hospital London UK

9. Sheba Medical Center Tel Aviv Israel

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13288

Reference67 articles.

1. World Health Organization.HIV/AIDS.2021.https://www.who.int/news‐room/fact‐sheets/detail/hiv‐aids. Accessed January 7 2022.

2. Investigational drugs in HIV: pros and cons of entry and fusion inhibitors;Venanzi Rullo E;Mol Med Rep,2019

3. EACS Guidelines version 11.0 October 2021.https://www.eacsociety.org/guidelines/eacs‐guidelines/. Accessed January 7 2022.

4. Characterization of Heavily Treatment-Experienced People With HIV and Impact on Health Care Resource Utilization in US Commercial and Medicare Advantage Health Plans

5. Pelchen‐MatthewsA BorgesAH ReekieJ et al.Prevalence and outcomes for heavily treatment‐experienced (HTE) individuals living with HIV in a European cohort. 10th IAS Conference on HIV Science (IAS 2019) July 21‐24 2019 Mexico City. Abstract TUPEB222.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA;Antiviral Therapy;2023-12

2. Gut Microbiome (Bacteria, Fungi, and Viruses) and HIV Infection: Revealing Novel Treatment Strategies;Molecular Nutrition & Food Research;2023-10-22

3. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV;American Journal of Health-System Pharmacy;2023-09-28

4. HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective;Antiviral Therapy;2023-09-25

5. Relapse of neurosymptomatic cerebrospinal fluid HIV RNA escape;HIV Medicine;2023-07-24